Related Experiment Videos
Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis
Veronika Brundula1, N Barry Rewcastle, Luanne M Metz
1Department of Clinical Neurosciences, University of Calgary, Canada.
Abstract:
Multiple sclerosis is characterized by the infiltration of leukocytes into the CNS. As matrix metalloproteinases (MMPs) facilitate the passage of leukocytes across matrix barriers, we tested the hypothesis that targeting MMPs could attenuate neuro-inflammation. We report that minocycline, a widely used generic drug with a good safety record, inhibited MMP activity, reduced production of MMP-9 and decreased the transmigration of T lymphocytes across a fibronectin matrix barrier. In addition, minocycline was efficacious against both mild and severe experimental autoimmune encephalomyelitis (EAE) in mice, an animal model of multiple sclerosis. When severe EAE was produced, minocycline pre-treatment delayed the course of the disease: when maximal disease activity occurred in vehicle-treated EAE mice, minocycline animals were relatively normal and had minimal signs of inflammation and demyelination in the CNS. When tested in mice afflicted with mild EAE, minocycline attenuated the clinical severity of disease throughout the course of treatment. These results indicate that minocycline may constitute a safe and inexpensive therapy for multiple sclerosis.
Insights
Minocycline, a safe drug, reduces inflammation and immune cell infiltration in the central nervous system. It effectively treats experimental autoimmune encephalomyelitis, a multiple sclerosis model, suggesting potential as a new therapy.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Multiple sclerosis involves leukocyte infiltration into the central nervous system (CNS).
- Matrix metalloproteinases (MMPs) are implicated in leukocyte migration across biological barriers.
- Targeting MMPs presents a potential strategy for mitigating neuroinflammation in multiple sclerosis.
Purpose of the Study:
- To investigate the potential of minocycline in attenuating neuroinflammation.
- To test the hypothesis that targeting MMPs can reduce neuroinflammation associated with multiple sclerosis.
Main Methods:
- Assessed minocycline's effect on MMP activity and MMP-9 production.
- Evaluated minocycline's impact on T lymphocyte transmigration across a fibronectin matrix.
- Determined minocycline's efficacy in mouse models of experimental autoimmune encephalomyelitis (EAE), a multiple sclerosis model.
Main Results:
- Minocycline inhibited MMP activity and reduced MMP-9 production.
- The drug decreased T lymphocyte transmigration across a fibronectin matrix.
- Minocycline demonstrated efficacy in both mild and severe cases of experimental autoimmune encephalomyelitis, delaying disease progression and reducing clinical severity.
Conclusions:
- Minocycline effectively inhibits key mechanisms of neuroinflammation.
- The drug shows significant therapeutic potential in experimental autoimmune encephalomyelitis, a model for multiple sclerosis.
- Minocycline may offer a safe and cost-effective treatment option for multiple sclerosis patients.